WO2011138265A3 - Dérivés d'indole et d'indazole utilisés comme antagonistes du récepteur de l'orexine - Google Patents

Dérivés d'indole et d'indazole utilisés comme antagonistes du récepteur de l'orexine Download PDF

Info

Publication number
WO2011138265A3
WO2011138265A3 PCT/EP2011/056938 EP2011056938W WO2011138265A3 WO 2011138265 A3 WO2011138265 A3 WO 2011138265A3 EP 2011056938 W EP2011056938 W EP 2011056938W WO 2011138265 A3 WO2011138265 A3 WO 2011138265A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor antagonists
indole
orexin receptor
indazole derivatives
compounds
Prior art date
Application number
PCT/EP2011/056938
Other languages
English (en)
Other versions
WO2011138265A2 (fr
Inventor
Jonathan Mark Bentley
Tara Davenport
Mark Slack
Original Assignee
Evotec Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec Ag filed Critical Evotec Ag
Publication of WO2011138265A2 publication Critical patent/WO2011138265A2/fr
Publication of WO2011138265A3 publication Critical patent/WO2011138265A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

L'invention concerne des composés de la formule (I) dans laquelle A, R1à R8 ont la signification mentionnée dans le descriptif et les revendications. Ces composés sont utiles comme antagonistes du récepteur de l'orexine. L'invention concerne également des compositions pharmaceutiques, la préparation de ces composés, ainsi que leur production et leur utilisation comme médicament.
PCT/EP2011/056938 2010-05-03 2011-05-02 Dérivés d'indole et d'indazole utilisés comme antagonistes du récepteur de l'orexine WO2011138265A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10161735 2010-05-03
EP10161735.5 2010-05-03

Publications (2)

Publication Number Publication Date
WO2011138265A2 WO2011138265A2 (fr) 2011-11-10
WO2011138265A3 true WO2011138265A3 (fr) 2015-06-25

Family

ID=42732252

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/056938 WO2011138265A2 (fr) 2010-05-03 2011-05-02 Dérivés d'indole et d'indazole utilisés comme antagonistes du récepteur de l'orexine

Country Status (1)

Country Link
WO (1) WO2011138265A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013217323A1 (en) 2012-02-07 2014-08-28 Eolas Therapeutics, Inc. Substituted prolines / piperidines as orexin receptor antagonists
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
ITMI20130830A1 (it) 2013-05-22 2014-11-23 Laboratorio Chimico Int Spa Procedimento per la preparazione di ivabradina
UY36272A (es) 2014-08-13 2016-02-29 Eolas Therapeutics Inc Difluoropirrolidinas como moduladores de los receptores de orexinas
JO3719B1 (ar) 2014-11-20 2021-01-31 Takeda Pharmaceuticals Co 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139
LT3414241T (lt) 2016-02-12 2022-08-25 Astrazeneca Ab Halogenu pakeisti piperidinai kaip oreksino receptoriaus moduliatoriai
WO2022119864A1 (fr) * 2020-12-01 2022-06-09 Purdue Research Foundation Composés pour le traitement du sars

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000046199A2 (fr) * 1999-02-05 2000-08-10 Astrazeneca Ab Composes chimiques
WO2000047576A1 (fr) * 1999-02-12 2000-08-17 Smithkline Beecham Plc Derives de cinnamide utilises en tant qu'antagonistes des recepteurs de l'orexine-1
WO2000047577A1 (fr) * 1999-02-12 2000-08-17 Smithkline Beecham Plc Derives de phenyluree et de phenylthiouree utilises comme antagonistes des recepteurs de l'orexine
WO2005040114A1 (fr) * 2003-10-14 2005-05-06 Oxagen Limited Composes presentant une activite antagoniste de crth2
WO2009105722A1 (fr) * 2008-02-22 2009-08-27 Irm Llc Composés et compositions comme modulateurs d'activité de gpr119

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60108236T2 (de) 2000-03-14 2005-12-22 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisochinolin-derivate
AU2001272476A1 (en) 2000-06-16 2001-12-24 Smithkline Beecham Plc Piperidines for use as orexin receptor antagonists
WO2002089800A2 (fr) 2001-05-05 2002-11-14 Smithkline Beecham P.L.C. Derives d'amines cycliques n-aroyl utilises comme antagonistes du recepteur d'orexine
CN1556705B (zh) 2002-07-09 2010-04-28 埃科特莱茵药品有限公司 7,8,9,10-四氢-6H-氮杂卓并、6,7,8,9-四氢-吡啶并和2,3-二氢-2H-吡咯并[2,1-b]-喹唑啉酮衍生物
EP2069332B1 (fr) 2006-08-15 2011-03-02 Actelion Pharmaceuticals Ltd. Composés d'azétidine en tant qu'antagonistes du recepteur orexin
EP2161266A1 (fr) 2008-08-22 2010-03-10 EVOTEC Neurosciences GmbH Dérivés de benzofurane en tant qu'antagonistes du récepteur de l'orexine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000046199A2 (fr) * 1999-02-05 2000-08-10 Astrazeneca Ab Composes chimiques
WO2000047576A1 (fr) * 1999-02-12 2000-08-17 Smithkline Beecham Plc Derives de cinnamide utilises en tant qu'antagonistes des recepteurs de l'orexine-1
WO2000047577A1 (fr) * 1999-02-12 2000-08-17 Smithkline Beecham Plc Derives de phenyluree et de phenylthiouree utilises comme antagonistes des recepteurs de l'orexine
WO2005040114A1 (fr) * 2003-10-14 2005-05-06 Oxagen Limited Composes presentant une activite antagoniste de crth2
WO2009105722A1 (fr) * 2008-02-22 2009-08-27 Irm Llc Composés et compositions comme modulateurs d'activité de gpr119

Also Published As

Publication number Publication date
WO2011138265A2 (fr) 2011-11-10

Similar Documents

Publication Publication Date Title
MX354102B (es) Derivados de bencimidazol-prolina.
IN2014CN04127A (fr)
MX2011011428A (es) Derivados de acido sulfamoilbenzoico como antagonistas de trpm8.
MX2010003001A (es) Derivados de quinolina como antagonistas del receptor de la 5-hidroxitriptamina 5a.
EP4268814A3 (fr) Composition pharmaceutique pour le traitement de l'oeil sec
WO2011138265A3 (fr) Dérivés d'indole et d'indazole utilisés comme antagonistes du récepteur de l'orexine
WO2012088038A3 (fr) Antagonistes de mch-1 consistant en tétrahydro-carbolines substituées par pipérazinone, leurs procédés de fabrication et utilisations
WO2009016564A3 (fr) Dérivés de 2-aza-bicyclo[3.3.0]octane
UA110310C2 (uk) Сполуки n-арилтриазолу як антагоністи рецепторів лізофосфатидної кислоти (lpar)
PH12014502789A1 (en) N-alkyltriazole compounds as lpar antagonists
ATE483707T1 (de) 2-cyclopropylthiazolderivate
WO2009016560A3 (fr) Dérivés de trans-3-aza-bicyclo[3.1.0]hexane
MX2010008993A (es) Derivados de 2-aza-biciclo-[2.2.1]heptano.
WO2009022311A3 (fr) Dérivés du 1,2-diamido-éthylène
WO2012088124A3 (fr) Antagonistes de la mch-1 à base de tétrahydro-azacarboline, leurs procédés de fabrication et leurs utilisations
UA107334C2 (ru) Производные аминоэфиров алкалоидов и их лекарственные композиции
UA102857C2 (en) Quinuclidine carbonate derivatives and use thereof
PH12014502364A1 (en) Substituted pyrazole compounds as lpar antagonists
WO2013190508A3 (fr) Dérivés de 1-[m-carboxamido(hétéro)arylméthyl]hétérocyclylcarboxamide
WO2010049449A3 (fr) Nouveaux sels de sunitinib
WO2011050054A3 (fr) Composés coumarine en tant que modulateurs de récepteurs possédant une utilité thérapeutique
WO2010140139A3 (fr) Formes cristallines de la 6-(1h-imidazol-1-yl)-2-phénylquinazoline et sels associés
WO2009034432A3 (fr) Nouveaux composés actifs utilisés comme antagonistes des récepteurs muscariniques
WO2011156045A3 (fr) Formulation d'ezatiostat en comprimés
WO2010131192A3 (fr) Nouveaux dérivés oxazolidinone

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11718036

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC DATED 04.02.2013

122 Ep: pct application non-entry in european phase

Ref document number: 11718036

Country of ref document: EP

Kind code of ref document: A2